Int J Angiol 2021; 30(04): 249-256
DOI: 10.1055/s-0041-1729920
Review Article

Cancer-Associated Atherothrombosis: The Challenge

Jochanan E. Naschitz
1   The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
2   Comprehensive Geriatric Ward, Bait Balev Nesher, Nesher, Israel
› Author Affiliations
Funding There was no funding to this work.

Abstract

The association between venous thrombosis and malignancy, having typical features of a paraneoplastic syndrome, has been established for a century. Currently, it is recognized that arterial thromboembolism (ATE) may also behave as a paraneoplastic syndrome. Recent matched cohort studies, systematic reviews, and observational studies concur in showing an increased incidence of acute coronary events, ischemic stroke, accelerated peripheral arterial disease, and in-stent thrombosis during the 6-month period before cancer diagnosis, peaking for 30 days immediately before cancer diagnosis. Cancer patients with ATE are at higher risk of in-hospital and long-term mortality as compared with noncancer patients. In the present review, we focus on the epidemiology, clinical variants and presentation, morbidity, mortality, primary and secondary prevention, and treatment of cancer-associated ATE. The awareness that cancer can be a risk factor for ATE and that cancer therapy can initiate cardiovascular complications make it mandatory to identify high-risk patients, modify preexistent cardiovascular risk factors, and adopt effective antithrombotic prophylaxis. For ATE prophylaxis, modifiable patient-related risk factors and oncology treatment–related factors are levers for intervention. Statins and platelet antiaggregants have been studied, but their efficacy for prevention of cancer-associated ATE remains to be demonstrated. Results of revascularization procedures for cancer-associated ATE are worse than for ATE in noncancer patients. It is important that a multidisciplinary approach is adopted for making informed decisions, by involving the vascular surgeon, interventional radiologist, oncologist, and palliative medicine, as well as the patients and their family.



Publication History

Article published online:
19 July 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. 2nd ed.. Vol. 3. Paris: J.-B. Baillière et fils; 1865: 695-727
  • 2 Sack Jr GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56 (01) 1-37
  • 3 Navi BB, Reiner AS, Kamel H. et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70 (08) 926-938
  • 4 Sundbøll J, Veres K, Horváth-Puhó E, Adelborg K, Sørensen HT. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation 2018; 138 (07) 669-677
  • 5 Brenner B, Bikdeli B, Tzoran I. et al; RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism. Am J Med 2018; 131 (09) 1095-1103
  • 6 Grilz E, Königsbrügge O, Posch F. et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica 2018; 103 (09) 1549-1556
  • 7 Naschitz JE, Kovaleva J, Shaviv N, Rennert G, Yeshurun D. Vascular disorders preceding diagnosis of cancer: distinguishing the causal relationship based on Bradford-Hill guidelines. Angiology 2003; 54 (01) 11-17
  • 8 Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017; 70 (20) 2536-2551
  • 9 Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 2017; 70 (20) 2552-2565
  • 10 Naschitz JE, Yeshurun D, Abrahamson J. Arterial occlusive disease in occult cancer. Am Heart J 1992; 124 (03) 738-745
  • 11 Naschitz JE, Schechter L, Chang JB. Intermittent claudication associated with cancer--case studies. Angiology 1987; 38 (09) 696-704
  • 12 Naschitz JE, Yeshurun D, Abrahamson J. et al. Ischemic heart disease precipitated by occult cancer. Cancer 1992; 69 (11) 2712-2720
  • 13 Navi BB, Reiner AS, Kamel H. et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019; 133 (08) 781-789
  • 14 Abbott JD, Ahmed HN, Vlachos HA, Selzer F, Williams DO. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 100 (02) 190-195
  • 15 Wang F, Gulati R, Lennon RJ. et al. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc 2016; 91 (12) 1680-1692
  • 16 Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 2012; 48 (01) 121-128
  • 17 Kaschwich M, Peters F, Hischke S. et al. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis. Vasa 2020; 49 (06) 493-499
  • 18 Navi BB, Singer S, Merkler AE. et al. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology 2014; 83 (01) 26-33
  • 19 Lee JM, Yoon C-H. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ J 2012; 42 (07) 487-491
  • 20 Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv 2017; 10 (22) 2334-2337
  • 21 Yu J, Li A, Laureano M, Crowther M. Frequency of arterial thromboembolism in populations with malignancies: a systematic review. Thromb Res 2019; 184: 16-23
  • 22 Prandoni P. Venous and arterial thrombosis: is there a link?. Adv Exp Med Biol 2017; 906: 273-283
  • 23 Tzoran I, Rebibo-Sabbah A, Brenner B, Aharon A. Disease dynamics in patients with acute myeloid leukemia: new biomarkers. Exp Hematol 2015; 43 (11) 936-943
  • 24 Faille D, Frere C, Cuisset T. et al. CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. J Thromb Haemost 2011; 9 (09) 1870-1873
  • 25 Nadir Y, Sarig G, Axelman E. et al. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thromb Res 2014; 134 (03) 639-642
  • 26 Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349 (02) 109-111
  • 27 Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of thrombosis in cancer patients. Cancer Treat Res 2019; 179: 11-36
  • 28 Mitrugno A, Tormoen GW, Kuhn P, McCarty OJT. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016; 30 (01) 11-19
  • 29 Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer; a resemblance with far-reaching implications. Arch Med Res 2017; 48 (01) 12-26
  • 30 Raposeiras Roubín S, Cordero A. The two-way relationship between cancer and atherosclerosis. Rev Esp Cardiol (Engl Ed) 2019; 72 (06) 487-494
  • 31 Seizer P, May AE. Platelets and matrix metalloproteinases. Thromb Haemost 2013; 110 (05) 903-909
  • 32 Heinmöller E, Weinel RJ, Heidtmann HH. et al. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol 1996; 122 (12) 735-744
  • 33 Herrmann J, Lerman A. The endothelium - the cardiovascular health barometer. Herz 2008; 33 (05) 343-353
  • 34 Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res 2018; 164 (Suppl. 01) S23-S28
  • 35 Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med 2020; 5 (04) 221-233
  • 36 Tuzovic M, Herrmann J, Iliescu C, Marmagkiolis K, Ziaeian B, Yang EH. Arterial thrombosis in patients with cancer. Curr Treat Options Cardiovasc Med 2018; 20 (05) 40
  • 37 Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SCEG, Eiger G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123 (01) 60-65
  • 38 Shai A, Rennert HS, Lavie O. et al. Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. J Thromb Thrombolysis 2014; 38 (01) 32-38
  • 39 Detrano R, Guerci AD, Carr JJ. et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358 (13) 1336-1345
  • 40 Sudhakar R. Response to treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012; 35 (10) 646
  • 41 Moran TB, Plana JC. Management of patients with acute coronary syndrome and cancer. Curr Cardiol Rep 2020; 22 (12) 159
  • 42 Gomes M, Khorana AA. Risk assessment for thrombosis in cancer. Semin Thromb Hemost 2014; 40 (03) 319-324
  • 43 Effron MB, Gibson CM. Dual (anticoagulant plus single antiplatelet) vs triple (anticoagulant plus dual antiplatelet) antithrombotic therapy - “real world” experience. Prog Cardiovasc Dis 2018; 60 (4–5): 531-536
  • 44 Iliescu CA, Grines CL, Herrmann J. et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista). Catheter Cardiovasc Interv 2016; 87 (05) E202-E223
  • 45 McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J 2017; 38 (47) 3488-3492
  • 46 Urban P, Mehran R, Colleran R. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019; 40 (31) 2632-2653
  • 47 Javid M, Magee TR, Galland RB. Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg 2008; 35 (01) 84-87
  • 48 Villemur B, Payraud E, Seetha V. et al. Arterial bypass iterative thrombosis and cancer: three cases [in French]. J Mal Vasc 2014; 39 (01) 14-17
  • 49 Balanescu DV, Donisan T, Deswal A. et al. Acute myocardial infarction in a high-risk cancer population: outcomes following conservative versus invasive management. Int J Cardiol 2020; 313: 1-8
  • 50 Elbadawi A, Elgendy IY, Ha LD. et al. National trends and outcomes of percutaneous coronary intervention in patients ≥70 years of age with acute coronary syndrome (from the National Inpatient Sample Database). Am J Cardiol 2019; 123 (01) 25-32
  • 51 Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary interventions in cancer patients. Expert Rev Cardiovasc Ther 2020; 18 (01) 25-32
  • 52 Iannaccone M, D'Ascenzo F, Vadalà P. et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018; 7 (07) 631-638
  • 53 Quintana RA, Monlezun DJ, Davogustto G. et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol 2020; 300: 106-112
  • 54 Piróth Z. PCI in patients with cancer: what is the evidence?. Int J Cardiol 2020; 304: 150-151
  • 55 Canale ML, Bisceglia I, Lestuzzi C, Parrini I. ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res 2019; 39 (09) 4619-4625
  • 56 Milazzo V, Cosentino N, Campodonico J. et al. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J Clin Med 2020; 9 (11) 3642